В США одобрен новый препарат для лечения атопического дерматита
6 апреля 2017
Фото: www.istockphoto.com/Tharakorn
Выпуск:
№159, апрель 2017
2008 просмотров
Array
(
[0] => Array
(
[ID] => 16466
[~ID] => 16466
[NAME] => apteka.ru/search/?q=%D1%81%D1%82%D0%B5%D0%BB%D0%BB%D0%B0%D0%BD%D0%B8%D0%BD&order=products%2Cmaterials&vendor=
[~NAME] => apteka.ru/search/?q=%D1%81%D1%82%D0%B5%D0%BB%D0%BB%D0%B0%D0%BD%D0%B8%D0%BD&order=products%2Cmaterials&vendor=
[DATE_ACTIVE_FROM] => 01.09.2019 11:17:00
[~DATE_ACTIVE_FROM] => 01.09.2019 11:17:00
[IBLOCK_ID] => 12
[~IBLOCK_ID] => 12
[PREVIEW_PICTURE] => 8171
[~PREVIEW_PICTURE] => 8171
)
[PROPERTIES] => Array
(
[SWF] => Array
(
[ID] => 99
[TIMESTAMP_X] => 2018-08-19 19:34:17
[IBLOCK_ID] => 12
[NAME] => Ссылка во флеше (link1)
[ACTIVE] => Y
[SORT] => 500
[CODE] => SWF
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => S
[ROW_COUNT] => 1
[COL_COUNT] => 50
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Ссылка во флеше (link1)
[~DEFAULT_VALUE] =>
)
[LINK] => Array
(
[ID] => 100
[TIMESTAMP_X] => 2018-08-19 19:34:17
[IBLOCK_ID] => 12
[NAME] => Ссылка (без протокола)
[ACTIVE] => Y
[SORT] => 500
[CODE] => LINK
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => S
[ROW_COUNT] => 1
[COL_COUNT] => 50
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] => 320465417
[VALUE] => apteka.ru/search/?q=%D0%B1%D0%B5%D1%80%D0%B5%D1%88&order=products%2Cmaterials&vendor=0
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] => apteka.ru/search/?q=%D0%B1%D0%B5%D1%80%D0%B5%D1%88&order=products%2Cmaterials&vendor=0
[~DESCRIPTION] =>
[~NAME] => Ссылка (без протокола)
[~DEFAULT_VALUE] =>
)
[WEBINARS] => Array
(
[ID] => 102
[TIMESTAMP_X] => 2020-11-05 08:23:57
[IBLOCK_ID] => 12
[NAME] => Вебинары
[ACTIVE] => Y
[SORT] => 500
[CODE] => WEBINARS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => E
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 5
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => Y
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] => EList
[USER_TYPE_SETTINGS] => Array
(
[size] => 20
[width] => 0
[group] => Y
[multiple] => Y
)
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Вебинары
[~DEFAULT_VALUE] =>
)
[TYPES] => Array
(
[ID] => 103
[TIMESTAMP_X] => 2018-08-20 03:08:52
[IBLOCK_ID] => 12
[NAME] => Где показывать
[ACTIVE] => Y
[SORT] => 500
[CODE] => TYPES
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => L
[ROW_COUNT] => 20
[COL_COUNT] => 30
[LIST_TYPE] => C
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => Y
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] => Array
(
[0] => 320482201
)
[VALUE] => Array
(
[0] => Страница статьи (273px)
)
[DESCRIPTION] => Array
(
[0] =>
)
[VALUE_ENUM] => Array
(
[0] => Страница статьи (273px)
)
[VALUE_XML_ID] => Array
(
[0] => ade3837e8e0b9a67adab1fec2bc57639
)
[VALUE_SORT] => Array
(
[0] => 500
)
[VALUE_ENUM_ID] => Array
(
[0] => 458
)
[~VALUE] => Array
(
[0] => Страница статьи (273px)
)
[~DESCRIPTION] => Array
(
[0] =>
)
[~NAME] => Где показывать
[~DEFAULT_VALUE] =>
)
[RUBRICS] => Array
(
[ID] => 104
[TIMESTAMP_X] => 2018-08-20 03:09:12
[IBLOCK_ID] => 12
[NAME] => Рубрики
[ACTIVE] => Y
[SORT] => 500
[CODE] => RUBRICS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => G
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 20
[TMP_ID] =>
[LINK_IBLOCK_ID] => 2
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => Y
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Рубрики
[~DEFAULT_VALUE] =>
)
[VIEWS] => Array
(
[ID] => 105
[TIMESTAMP_X] => 2018-08-19 23:38:24
[IBLOCK_ID] => 12
[NAME] => Показы
[ACTIVE] => Y
[SORT] => 500
[CODE] => VIEWS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => N
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Показы
[~DEFAULT_VALUE] =>
)
[CLICKS] => Array
(
[ID] => 106
[TIMESTAMP_X] => 2018-08-19 23:38:24
[IBLOCK_ID] => 12
[NAME] => Клики
[ACTIVE] => Y
[SORT] => 500
[CODE] => CLICKS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => N
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Клики
[~DEFAULT_VALUE] =>
)
[ARTICLE] => Array
(
[ID] => 116
[TIMESTAMP_X] => 2019-05-17 13:18:54
[IBLOCK_ID] => 12
[NAME] => Статьи
[ACTIVE] => Y
[SORT] => 500
[CODE] => ARTICLE
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => E
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 2
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] => EList
[USER_TYPE_SETTINGS] => Array
(
[size] => 20
[width] => 0
[group] => N
[multiple] => Y
)
[HINT] =>
[PROPERTY_VALUE_ID] => Array
(
[0] => 320482202
)
[VALUE] => Array
(
[0] => 32724
)
[DESCRIPTION] => Array
(
[0] =>
)
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] => Array
(
[0] => 32724
)
[~DESCRIPTION] => Array
(
[0] =>
)
[~NAME] => Статьи
[~DEFAULT_VALUE] =>
)
[CRIB] => Array
(
[ID] => 117
[TIMESTAMP_X] => 2019-05-30 07:53:16
[IBLOCK_ID] => 12
[NAME] => Шпаргалки
[ACTIVE] => Y
[SORT] => 500
[CODE] => CRIB
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => E
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 3
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] => EList
[USER_TYPE_SETTINGS] => Array
(
[size] => 20
[width] => 0
[group] => N
[multiple] => N
)
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Шпаргалки
[~DEFAULT_VALUE] =>
)
)
[1] => Array
(
[ID] => 15705
[~ID] => 15705
[NAME] => Стелланин апрель
[~NAME] => Стелланин апрель
[DATE_ACTIVE_FROM] => 01.04.2019 13:37:00
[~DATE_ACTIVE_FROM] => 01.04.2019 13:37:00
[IBLOCK_ID] => 12
[~IBLOCK_ID] => 12
[PREVIEW_PICTURE] => 7449
[~PREVIEW_PICTURE] => 7449
)
[2] => Array
(
[ID] => 32741
[~ID] => 32741
[NAME] => Береш Май Обзор писем РЗН
[~NAME] => Береш Май Обзор писем РЗН
[DATE_ACTIVE_FROM] => 28.05.2020 08:53:00
[~DATE_ACTIVE_FROM] => 28.05.2020 08:53:00
[IBLOCK_ID] => 12
[~IBLOCK_ID] => 12
[PREVIEW_PICTURE] => 10191
[~PREVIEW_PICTURE] => 10191
)
)

В США одобрен новый препарат для лечения атопического дерматита
Управление по санитарному надзору за качеством пищевых продуктов и медикаментов США (FDA) одобрило моноклональные антитела дупилумаб (dupilumab) в форме подкожных инъекций для атопического дерматита у взрослых умеренной и тяжелой степени. Соответствующий документ был принят 28 марта 2017 года.
Препарат предназначен для пациентов, у которых экзема не поддается лечению местными средствами или для их применения имеются противопоказания. Дупилумаб может использоваться как совместно с кортикостероидными препаратами, так и без них.
Атопический дерматит — хроническое воспалительное заболевание кожи аллергической природы, которое может существенно снижать качество жизни. При атопическом дерматите характерны кожные высыпания в виде красных чешуйчатых бляшек и зуд. В результате расчесывания кожа огрубевает и утолщается.
Активным компонентом нового препарата являются антитела к субъединице общей для двух провоспалительных интерлейкинов: ИЛ-4 и ИЛ-13. В результате связывания с этими интерлейкинами дупилумаб ингибирует воспалительную реакцию, лежащую в основе атопического дерматита.
Исследования свойств нового препарата проводились в трех плацебо-контролируемых клинических испытаниях, в общей сложности охвативших 2119 взрослых участников с атопическим дерматитом от средней до тяжелой формы. Всем участвовавшим пациентам местные препараты (глюкокортикостероиды и ингибиторы кальциневрина) должным образом не помогали контролировать процесс.
В группе проходивших лечение дупилумабом (одна инъекция в неделю или в две недели) по сравнению с группой плацебо (одна инъекция в неделю) достигнут достоверно больший отклик, определяемый чистой или почти чистой кожей, а также снижением зуда после 16 недель лечения.
В клинических испытаниях была показана результативность дупилумаба при лечении других заболеваний со сходной этиологией — астмы и хронического полипозного синусита, однако одобрения FDA на расширенные показания к применению дупилумаба пока не получено.
Источники:
Medical news todayU. S. Food and Drug AdministrationThe New England Journal of MedicineDrugs.com
зарегистрированным пользователям